Pfizer PFE-2.36%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 1.12%increase; green up pointing triangle for 2.50 billion ...

在辉瑞宣布出售Haleon股份后，市场反应十分迅速。众多分析师对辉瑞的这一决定表示关注与分析。在短期内，Haleon股价可能遭受一定压力，这对于持有Haleon股票的投资者而言，无疑是一个冲击。然而，从长远来看，卖出Haleon股票能够释放辉瑞的资金，而这些资金可以被更有效地投入其他更具潜力的项目中。

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million ...

Jan 15 (Reuters) - Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare ...

(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

(Reuters) -Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner ...

(Alliance News) - Pfizer Inc is selling 700 million shares in Haleon PLC, more than halving its remaining stake, according to a statement from JPMorgan Securities on Tuesday. Weybridge-based ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

Pfizer plans to cut its stake in Haleon through an accelerated bookbuilding process to institutional investor, starting immediately. The New York drugmaker said Tuesday that the proposed sale ...

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...